Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Induction of PGE2 in IL-1beta stimulated human A549 cells at 4 nM incubated for 24 hrs by ELISA assay
Assay data:2 Active, 2 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by Target
Induction of PGE2 in IL-1beta stimulated human A549 cells at 20 nM incubated for 24 hrs by ELISA assay
Induction of PGE2 in IL-1beta stimulated human A549 cells at 2500 nM incubated for 24 hrs by ELISA assay
Assay data:1 Active, 1 Tested
Antagonist activity at human EP3 receptor transfected in CHO/Galpha16 cells preincubated for 15 mins followed by PGE2 addition by calcium flux assay
Assay data:10 Tested
SummaryPubMed CitationRelated BioAssays by Target
Antagonist activity at human EP3 receptor expressed in CHO-K1 cells assessed as reduction in sulprostone induced inhibition of forskolin stimulated cAMP production incubated for 30 mins by TR-FRET assay
Assay data:25 Active, 1 Activity ≤ 1 nM, 25 Activity ≤ 1 µM, 25 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Displacement of [3H]-PGE2 from human EP3 receptor assessed as inhibition constant incubated for 2 hrs by TopCount scintillation counting method
Assay data:27 Active, 6 Activity ≤ 1 nM, 27 Activity ≤ 1 µM, 27 Tested
EP3 Binding Activity Measurement from US Patent US11479550: "EP4 antagonist"
Assay data:5 Active, 2 Activity ≤ 1 µM, 6 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by DepositorRelated BioAssays by Target
Cell Based Assay from US Patent US9422273: "Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response"
Assay data:5 Active, 5 Activity ≤ 1 nM, 5 Activity ≤ 1 µM, 5 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
FLIPR Assay from US Patent US9394273: "Therapeutic prostaglandin receptor agonists"
Assay data:10 Active, 4 Activity ≤ 1 µM, 10 Tested
EP3 Radioligand SPA Binding Assay from US Patent US9278953: "Antagonists of prostaglandin EP3 receptor"
Assay data:14 Active, 14 Activity ≤ 1 µM, 14 Tested
Radioligand Binding from US Patent US9156810: "Treatment of inflammatory bowel disease"
Assay data:20 Active, 17 Activity ≤ 1 µM, 22 Tested
In Vitro Binding Assay from US Patent US9000043: "Phenoxyethoxy compounds"
Assay data:1 Active, 1 Activity ≤ 1 nM, 1 Activity ≤ 1 µM, 1 Tested
In Vitro Binding Assay from US Patent US8962659: "Phenoxyethyl piperidine compounds"
Assay data:1 Active, 1 Activity ≤ 1 µM, 1 Tested
In Vitro Binding Assay from US Patent US8933098: "Dimethyl-benzoic acid compounds"
Radioligand SPA Binding Assay from US Patent US9738626: "Antagonists of prostaglandin EP3 receptor"
Assay data:7 Active, 7 Activity ≤ 1 µM, 7 Tested
Prostanoid EP3 Eurofins-Panlabs radioligand binding assay
Assay data:1 Tested
SummaryRelated BioAssays by Target
Assay data:4 Tested
EP3 Eurofins Bayer panel
PRESTO-Tango GPCRome screening (PTGER3)
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on